AML KEMOTERAPİ PROTOKOLLERİ

Kaynaklar:

1-Lowenberg, B. G. J. Ossenkoppele, W. van Putten, et al. 2009. "High-dose daunorubicin in older patients with acute myeloid leukemia." N Engl J Med 361(13):1235-1248. 

2- Fernandez, H. F., Z. Sun, X. Yao, et al. 2009. "Anthracycline dose intensification in acute myeloid leukemia." N Engl J Med 361(13):1249-1259. 

3- Lee, J. H., Y. D. Joo, H. Kim, et al. 2011. "A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia." Blood 118(14):3832-3841. 

4- Burnett, A. K., Russell, N. H., Hills, R. K., et al. 2015. “A randomised comparison of daunorubicin 90mg/m2 vs 60mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.” Blood 125(25):3878-3885. 

5- Dohner, H., E. Estey, D. Grimwade, et al. 2017. "Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel." Blood 129(4):424-447. 

6- NCCN Clinical Practice Guidelines in Oncology - Acute Myeloid Leukaemia - Version 1.2017 www.nccn.org 

7- Luskin, M. R., Lee, J., Fernandez, H. F., et al. 2016. “Benefit of high-dose daunorubicin in AML induction extends across cytogenetics and molecular groups.” Blood 127(12):1551-1558.

8- Burnett A. K., N. H. Russell, R. K. Hills, et al. 2016. Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia. Blood 128:449-452.